BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38077398)

  • 1. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
    Filioglou D; Husnain M; Khurana S; Simpson RJ; Katsanis E
    Front Immunol; 2023; 14():1329850. PubMed ID: 38077398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
    Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
    Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
    Green S; Schultz L
    Curr Oncol Rep; 2023 Aug; 25(8):841-846. PubMed ID: 37099243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
    Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
    Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
    Chong EA; Chong ER; Therwhanger D; Nasta SD; Landsburg DJ; Barta SK; Svoboda J; Gerson JN; Ghilardi G; Paruzzo L; Fraietta JA; Weber E; Stefano N; Porter DL; Frey NV; Garfall AL; Ruella M; Schuster SJ
    Transplant Cell Ther; 2024 Mar; ():. PubMed ID: 38494076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
    Lickefett B; Chu L; Ortiz-Maldonado V; Warmuth L; Barba P; Doglio M; Henderson D; Hudecek M; Kremer A; Markman J; Nauerth M; Negre H; Sanges C; Staber PB; Tanzi R; Delgado J; Busch DH; Kuball J; Luu M; Jäger U
    Front Immunol; 2023; 14():1303935. PubMed ID: 38187393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
    Sidana S; Hosoya H; Jensen A; Liu L; Goyal A; Hovanky V; Sahaf B; Bharadwaj S; Latchford T; Arai S; Leahy S; Mei M; Budde LE; Muffly LS; Frank MJ; Dahiya S; Htut M; Miklos D; Janakiram M
    Blood Cancer J; 2023 Oct; 13(1):158. PubMed ID: 37833271
    [No Abstract]   [Full Text] [Related]  

  • 9. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
    Ghilardi G; Paruzzo L; Svoboda J; Chong EA; Shestov AA; Chen L; Cohen IJ; Gabrielli G; Nasta SD; Porazzi P; Landsburg DJ; Gerson JN; Carter J; Barta SK; Yelton R; Pajarillo R; Patel V; White G; Ballard HJ; Weber E; Napier E; Chong ER; Fraietta JA; Garfall AL; Porter DL; Milone MC; O'Connor R; Schuster SJ; Ruella M
    Blood Adv; 2024 Feb; 8(3):653-666. PubMed ID: 38113468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
    J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives.
    Costa BA; Mouhieddine TH; Ortiz RJ; Richter J
    Crit Rev Oncol Hematol; 2023 Jul; 187():104040. PubMed ID: 37244325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Zafar A; Huang CY; Lo M; Arora S; Chung A; Wong SW; Wolf J; Martin TG; Shah N; Banerjee R
    Transplant Cell Ther; 2023 Aug; 29(8):504.e1-504.e7. PubMed ID: 37244643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
    Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
    Liang Z; Zhang H; Shao M; Cui Q; Wu Z; Xiao L; Huang H; Hu Y
    Medicine (Baltimore); 2020 Oct; 99(43):e22510. PubMed ID: 33120740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
    De Matteis S; Dicataldo M; Casadei B; Storci G; Laprovitera N; Arpinati M; Maffini E; Cortelli P; Guarino M; Vaglio F; Naddeo M; Sinigaglia B; Zazzeroni L; Guadagnuolo S; Tomassini E; Bertuccio SN; Messelodi D; Ferracin M; Bonafè M; Zinzani PL; Bonifazi F
    Front Immunol; 2022; 13():1058126. PubMed ID: 36726971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
    Hegde M; Navai S; DeRenzo C; Joseph SK; Sanber K; Wu M; Gad AZ; Janeway KA; Campbell M; Mullikin D; Nawas Z; Robertson C; Mathew PR; Zhang H; Mehta B; Bhat RR; Major A; Shree A; Gerken C; Kalra M; Chakraborty R; Thakkar SG; Dakhova O; Salsman VS; Grilley B; Lapteva N; Gee A; Dotti G; Bao R; Salem AH; Wang T; Brenner MK; Heslop HE; Wels WS; Hicks MJ; Gottschalk S; Ahmed N
    Nat Cancer; 2024 Apr; ():. PubMed ID: 38658775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.